Deletion of IFN-α/βR, the receptor for type 1 IFN, but not Rip3, significantly inhibited the release of IL-1α and IL-1β in endotoxemia (Fig. 4a-b). The gene discussed is RIPK3; the disease is serum lipopolysaccharide activity.